Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd > NOX

<< Previous

Bullboard Posts

Next >>

Comment by LMA74on Feb 27, 2013 12:12pm

177 Views

Post# 21049055

RE: RE: RE: NOX

Let us try to keep the 50MA 0.315 today, that would be a good thing.

End March the updated 43-101 with +/- 3 mil. ounces, before that some Marban assays (1.6 mil drill campaign) and end of March, beginning of April the Aurizon decision.

Enough cash to go alone or Aurizon continuing with Phase3, or stop and 11 mil. free money and 3 mil. ounces.

All said before but what not to like.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth